Hybrid lipid nanoparticles with tumor antigen-primed dendritic cell membranes for post-surgical tumor immunotherapy
Journal of Controlled Release · 2025-03 · 379 · 537-548
DOI: 10.1016/j.jconrel.2025.01.027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2025-03. Verfasst von Dongyoon Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea. Hauptthemen laut MEDLINE: Nanoparticles, Dendritic Cells, Immunotherapy, Antigens, Neoplasm. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Korea Evaluation Institute of Industrial Technology, Korea Ministry of Trade Industry and Energy, National Research Foundation of Korea.
Abstract (Originalsprache)
Post-surgical tumor recurrence poses a major challenge in cancer treatment due to residual tumor cells and surgery-induced immunosuppression. Here, we developed hybrid nanoparticles, termed T-DCNPs, designed to promote antigen-specific activation of cytotoxic CD8+ T cells while concurrently inhibiting immunosuppressive pathways within the tumor microenvironment. T-DCNPs were formulated by co-extruding lipid nanoparticles containing a transforming growth factor β inhibitor with dendritic cells that were pre-treated with autologous neoantigens derived from surgically excised tumors. By using whole tumor antigens rather than specific peptides, T-DCNPs effectively overcame tumor heterogeneity and elicited a robust, targeted immune response. In vitro studies showed that T-DCNPs enhanced CD8+ T cell proliferation and reduced programmed death-1 (PD-1) expression, leading to increased antitumor cytotoxicity. In vivo experiments, involving intratumoral injections of T-DCNPs in distant tumor and post-surgical melanoma models, demonstrated a significant reduction in distant tumor growth, decreased recurrence rates, and extended survival compared to control groups. Flow cytometry and immunohistochemistry analyses further confirmed the enhanced infiltration of activated CD8+ T cells and a marked reduction in immunosuppressive markers, including PD-1 and Foxp3, within the treated tumors. These results suggest that T-DCNPs, through the dual mechanisms of tumor antigen-specific T cell activation and immune modulation, offer a promising strategy to prevent tumor recurrence following surgery and could potentially improve the efficacy of postoperative cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea.
- College of Pharmacy, Korea University, Sejong 30019, Republic of Korea. Electronic address: ljw1112@korea.ac.kr.
- College of Pharmacy, Sookmyung Women's University, Seoul 04310, Republic of Korea. Electronic address: junho_byun@sookmyung.ac.kr.
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 08826, Republic of Korea. Electronic address: ohyk@snu.ac.kr.
Förderung
- Korea Evaluation Institute of Industrial Technology
- Korea Ministry of Trade Industry and Energy
- National Research Foundation of Korea
- Korea Ministry of Science and ICT
Zitieren
APA
Kim, D., Choi, J., Jin, D., Xu, E., Lee, J., Byun, J., & Oh, Y. K. (2025). Hybrid lipid nanoparticles with tumor antigen-primed dendritic cell membranes for post-surgical tumor immunotherapy. Journal of Controlled Release, 379, 537-548. https://doi.org/10.1016/j.jconrel.2025.01.027
Vancouver
Kim D, Choi J, Jin D, Xu E, Lee J, Byun J, et al. Hybrid lipid nanoparticles with tumor antigen-primed dendritic cell membranes for post-surgical tumor immunotherapy. Journal of Controlled Release. 2025;379:537-548. doi:10.1016/j.jconrel.2025.01.027
BibTeX
@article{Kim2025,
author = {Kim, Dongyoon and Choi, Jaehyun and Jin, Dongun and Xu, Enzhen and Lee, Jaiwoo and Byun, Junho and Oh, Yu-Kyoung},
title = {Hybrid lipid nanoparticles with tumor antigen-primed dendritic cell membranes for post-surgical tumor immunotherapy},
journal = {Journal of Controlled Release},
year = {2025},
volume = {379},
pages = {537--548},
doi = {10.1016/j.jconrel.2025.01.027}
}
EUVIMED